Recombinant Anti-Cytokeratin 10 antibody [rKRT10/1275] - BSA and Azide free (ab236306)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [rKRT10/1275] to Cytokeratin 10 - BSA and Azide free
- Suitable for: IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Cytokeratin 10 antibody [rKRT10/1275] - BSA and Azide free
See all Cytokeratin 10 primary antibodies -
Description
Mouse monoclonal [rKRT10/1275] to Cytokeratin 10 - BSA and Azide free -
Host species
Mouse -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein corresponding to Human Cytokeratin 10 aa 1 to the C-terminus.
Database link: P13645 -
Positive control
- IHC-P: Human skin tissue.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A/G purified -
Purification notes
Purified from Bioreactor Concentrate by Protein A/G. -
Clonality
Monoclonal -
Clone number
rKRT10/1275 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab236306 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
Use a concentration of 0.1 - 0.2 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
(Primary incubation for 30 min at room temperature). |
Notes |
---|
IHC-P
Use a concentration of 0.1 - 0.2 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. (Primary incubation for 30 min at room temperature). |
Target
-
Tissue specificity
Seen in all suprabasal cell layers including stratum corneum. -
Involvement in disease
Defects in KRT10 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
Defects in KRT10 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months. -
Sequence similarities
Belongs to the intermediate filament family. - Information by UniProt
-
Database links
- Entrez Gene: 3858 Human
- Omim: 148080 Human
- SwissProt: P13645 Human
- Unigene: 99936 Human
-
Alternative names
- BCIE antibody
- BIE antibody
- CK 10 antibody
see all
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (0)
ab236306 has not yet been referenced specifically in any publications.